Pub. Date : 2019 Apr
PMID : 30843662
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer. | Crizotinib | tumor protein p53 | Homo sapiens |
| 2 | The clinicopathologic features of the TP53 mutations and its impact on the effect of crizotinib treatment were analyzed. | Crizotinib | tumor protein p53 | Homo sapiens |
| 3 | CONCLUSIONS: TP53 mutations, especially nondisruptive mutations, negatively affected the response to crizotinib and correlated with shorter PFS in ALK-rearranged NSCLC patients. | Crizotinib | tumor protein p53 | Homo sapiens |